HEALTH CARE AUTHORITY: $82.7M Department of Health and Human Services Grant
Summary
This $82.7M grant from SAMHSA to the Washington State Health Care Authority funds opioid response initiatives including prevention, treatment, and recovery services. As the recipient is a state agency with no public parent company, there is no direct stock-level impact, though the grant signals continued federal prioritization of opioid crisis funding.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The $82.7M SAMHSA grant to Washington State supports opioid prevention, treatment, and recovery, but has no direct publicly traded recipient.
- 2.No related legislation in the provided list directly connects to this opioid response contract.
- 3.Investors should monitor broader federal spending on addiction treatment as a sector tailwind, but this specific award does not create actionable stock-level catalysts.
Market Implications
As a grant to a state agency, this contract does not directly impact any publicly traded company's revenue or earnings. The broader healthcare sector, particularly companies involved in opioid addiction treatment (e.g., makers of buprenorphine, naloxone, and behavioral health platforms), may benefit indirectly from sustained federal focus, but no specific ticker movements can be tied to this award.
Full Analysis
The Substance Abuse and Mental Health Services Administration (SAMHSA) awarded an $82.7 million project grant to the Washington State Health Care Authority for the State Opioid Response (SOR) IV program. The grant supports a comprehensive response to the opioid epidemic, including community prevention coalitions, medication-assisted treatment (MOUD), harm reduction services, and recovery support. The award covers a three-year period from September 2024 to September 2027.
Because the recipient is a government agency and not a publicly traded company, no direct stock tickers are affected. However, this contract contributes to the broader healthcare sector's tailwind from sustained federal spending on addiction and mental health services. Companies providing opioid treatment medications (e.g., buprenorphine, naloxone) and behavioral health services may see indirect demand, but the connection is too diffuse for specific ticker attribution.
No related bills in the provided set directly authorized or appropriated funds for this specific grant. The listed bills cover diverse topics such as charter schools, Iran hostilities, and vehicle loan interest deductions, none of which align with the opioid response focus of this contract.
Downstream beneficiaries could include pharmaceutical manufacturers of addiction treatment drugs and tele-health platforms, but these are not identified as subcontractors in the award description. The grant's emphasis on harm reduction supplies and nicotine replacement therapy suggests potential demand for those product categories.
Historically, state opioid response grants have been renewed annually, providing consistent funding streams for public health agencies. Private-sector companies with exposure to opioid treatment markets often see steady, not volatile, revenue from such grants.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Contract Details
Recipient
HEALTH CARE AUTHORITY
Award Amount
$82,727,977
Awarding Agency
Department of Health and Human Services
Sub-Agency
Substance Abuse and Mental Health Services Administration
Contract Type
PROJECT GRANT (B)
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →